Please login to the form below

Not currently logged in

Novo’s oral diabetes drug hits the mark again

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

Novo Nordisk

Novo Nordisk’s much-anticipated orally formulated version of diabetes treatment Ozempic (semaglutide) has generated more positive data in a late stage trial, demonstrating its effectiveness at blood sugar reductions and weight loss.

The 26-week phase IIIa trial, also known as PIONEER 5, investigated oral semaglutide in 324 patients with type 2 diabetes and who have a kidney-impairment, a serious diabetes complication.

The aim of the trial was to measure glycated haemoglobin (blood sugar) levels (HbA1c) in patients on Novo’s drug compared to placebo, and according to the company, the drug demonstrated a statistically significant and superior improvement in HbA1c.

Furthermore, those treated with Novo’s GLP-1 agonist achieved statistically significant and superior reductions in body weight compared to placebo at week 26.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: “The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide."

"Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people."

The drug could be a massive game changer if it reaches market, particularly with its potential in enhancing patient adherence.

If approved the drug would give the Danish group a leg up on Eli Lilly’s Jardiance, as it recently outperformed the drug during a phase IIIa trial.

Article by
Gemma Jones

21st August 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...